Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Public ClinicalTrials.gov record NCT01054885. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Study identification
- NCT ID
- NCT01054885
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,226 participants
Conditions and interventions
Conditions
Interventions
- FF Inhalation Powder Drug
- FF/GW642444 Inhalation Powder Drug
- GW642444 Inhalation Powder Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2009
- Primary completion
- Jan 31, 2011
- Completion
- Feb 7, 2011
- Last update posted
- Jan 23, 2018
2009 – 2011
United States locations
- U.S. sites
- 49
- U.S. states
- 19
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35235 | — |
| GSK Investigational Site | Jasper | Alabama | 35501 | — |
| GSK Investigational Site | Lakewood | California | 90712 | — |
| GSK Investigational Site | Long Beach | California | 90808 | — |
| GSK Investigational Site | Los Angeles | California | 90048 | — |
| GSK Investigational Site | Monterey Park | California | 91754 | — |
| GSK Investigational Site | National City | California | 91950 | — |
| GSK Investigational Site | Oxnard | California | 93030-5841 | — |
| GSK Investigational Site | San Diego | California | 92120 | — |
| GSK Investigational Site | Santa Monica | California | 90404 | — |
| GSK Investigational Site | Wilmington | Delaware | 19805 | — |
| GSK Investigational Site | Bay Pines | Florida | 33744 | — |
| GSK Investigational Site | Brandon | Florida | 33511 | — |
| GSK Investigational Site | Clearwater | Florida | 33756 | — |
| GSK Investigational Site | Cocoa | Florida | 32927 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33316 | — |
| GSK Investigational Site | Pensacola | Florida | 32503 | — |
| GSK Investigational Site | Decatur | Georgia | — | — |
| GSK Investigational Site | Gainesville | Georgia | — | — |
| GSK Investigational Site | Martinez | Georgia | 30907 | — |
| GSK Investigational Site | Lenexa | Kansas | 66215 | — |
| GSK Investigational Site | Wheaton | Maryland | 20902 | — |
| GSK Investigational Site | Saint Charles | Missouri | 63301 | — |
| GSK Investigational Site | Cherry Hill | New Jersey | 08003 | — |
| GSK Investigational Site | Ocean City | New Jersey | 7712 | — |
| GSK Investigational Site | Brooklyn | New York | 11229 | — |
| GSK Investigational Site | Elizabeth City | North Carolina | 27909 | — |
| GSK Investigational Site | Statesville | North Carolina | 28625 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45231 | — |
| GSK Investigational Site | Dayton | Ohio | 45439 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73103 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74136-8303 | — |
| GSK Investigational Site | Medford | Oregon | 97504 | — |
| GSK Investigational Site | Portland | Oregon | 97213 | — |
| GSK Investigational Site | Columbia | South Carolina | 29203 | — |
| GSK Investigational Site | Easley | South Carolina | 29640 | — |
| GSK Investigational Site | Gaffney | South Carolina | 29340 | — |
| GSK Investigational Site | Orangeburg | South Carolina | 29118 | — |
| GSK Investigational Site | Seneca | South Carolina | 29678 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | Union | South Carolina | 29379 | — |
| GSK Investigational Site | Johnson City | Tennessee | 37601 | — |
| GSK Investigational Site | New Tazewell | Tennessee | 37825 | — |
| GSK Investigational Site | Boerne | Texas | 78006 | — |
| GSK Investigational Site | Corsicana | Texas | 75110 | — |
| GSK Investigational Site | Kingwood | Texas | 77339 | — |
| GSK Investigational Site | Temple | Texas | 76508 | — |
| GSK Investigational Site | Fredericksburg | Virginia | 22401 | — |
| GSK Investigational Site | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.
Recently updated Pulmonary Disease, Chronic Obstructive trials
Other public records listing Pulmonary Disease, Chronic Obstructive. Sorted by last update posted; newest first. Not a recommendation.
- NCT07759245: A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) Not yet recruiting
- NCT07177339: eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Recruiting
- NCT07714252: Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD Not yet recruiting
- NCT05718102: Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD Active, not recruiting
- NCT04669743: Innate Immunity in Ozone-induced Airway Inflammation in COPD Active, not recruiting
- NCT06961214: Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01054885, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 23, 2018 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01054885 live on ClinicalTrials.gov.